- Report
- January 2024
- 200 Pages
Global
From €4038EUR$4,150USD£3,459GBP
- Report
- February 2021
- 360 Pages
United States
From €2335EUR$2,400USD£2,000GBP
- Report
- February 2019
- 105 Pages
Global
From €1255EUR$1,290USD£1,075GBP
- Report
- June 2019
- 16 Pages
Global
€9730EUR$10,000USD£8,335GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €486EUR$500USD£417GBP
- Report
- January 2019
- 35 Pages
Global
From €973EUR$1,000USD£834GBP
- Report
- June 2019
- 16 Pages
Global
€9730EUR$10,000USD£8,335GBP
- Report
- November 2023
- 35 Pages
Global
From €5663EUR$5,820USD£4,851GBP
Epzicom is a market of HIV/AIDS drugs, specifically a combination of two antiretroviral drugs, abacavir and lamivudine. It is used to treat HIV-1 infection in adults and children over the age of three months. The combination of these two drugs helps to reduce the amount of HIV in the body, allowing the immune system to recover and fight off infections. Epzicom is also used to reduce the risk of HIV transmission from mother to child during pregnancy.
Epzicom is a widely used HIV/AIDS drug, with many companies producing and distributing it. Some of these companies include GlaxoSmithKline, Bristol-Myers Squibb, Merck, and Gilead Sciences. Show Less Read more
